Jyong Biotech Ltd. Ordinary Shares (MENS) - Net Assets
Based on the latest financial reports, Jyong Biotech Ltd. Ordinary Shares (MENS) has net assets worth $-24.91 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($20.78 Million) and total liabilities ($45.68 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. See MENS net asset quality index to measure how much of total assets are equity-financed.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-24.91 Million |
| % of Total Assets | -119.87% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Jyong Biotech Ltd. Ordinary Shares - Net Assets Trend (2020–2025)
This chart illustrates how Jyong Biotech Ltd. Ordinary Shares's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see how much is Jyong Biotech Ltd. Ordinary Shares worth.
Annual Net Assets for Jyong Biotech Ltd. Ordinary Shares (2020–2025)
The table below shows the annual net assets of Jyong Biotech Ltd. Ordinary Shares from 2020 to 2025. Also explore net asset growth rate of Jyong Biotech Ltd. Ordinary Shares to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-24.91 Million | +31.80% |
| 2024-12-31 | $-36.52 Million | -7.18% |
| 2023-12-31 | $-34.07 Million | -14.99% |
| 2022-12-31 | $-29.63 Million | -27.04% |
| 2021-12-31 | $-23.32 Million | -21.46% |
| 2020-12-31 | $-19.20 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Jyong Biotech Ltd. Ordinary Shares's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2291800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.00K | % |
| Other Comprehensive Income | $682.00K | % |
| Other Components | $12.16 Million | % |
| Total Equity | $-24.91 Million | 100.00% |
Jyong Biotech Ltd. Ordinary Shares Competitors by Market Cap
The table below lists competitors of Jyong Biotech Ltd. Ordinary Shares ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Valens
NYSE:VLN
|
$156.62 Million |
|
Dong Hai JSC of Bentre
VN:DHC
|
$156.63 Million |
|
Sparebanken Ost
OL:SPOG
|
$156.63 Million |
|
Nusantara Pelabuhan Handal Tbk PT
JK:PORT
|
$156.64 Million |
|
Huons Global Co. Ltd
KQ:084110
|
$156.59 Million |
|
Solocal Group SA
PA:LOCAL
|
$156.53 Million |
|
HansBiomed Corporation
KQ:042520
|
$156.48 Million |
|
Ecomate Holdings Bhd
KLSE:0239
|
$156.41 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Jyong Biotech Ltd. Ordinary Shares's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -36,519,000 to -24,906,000, a change of 11,613,000.
- Net loss of 4,671,000 reduced equity.
- New share issuances of 17,771,000 increased equity.
- Other comprehensive income decreased equity by 439,000.
- Other factors decreased equity by 1,048,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-4.67 Million | -18.75% |
| Share Issuances | $17.77 Million | +71.35% |
| Other Comprehensive Income | $-439.00K | -1.76% |
| Other Changes | $-1.05 Million | -4.21% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Jyong Biotech Ltd. Ordinary Shares's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | $-0.27 | $2.14 | x |
| 2021-12-31 | $-0.31 | $2.14 | x |
| 2022-12-31 | $-0.39 | $2.14 | x |
| 2023-12-31 | $-0.45 | $2.14 | x |
| 2024-12-31 | $-0.48 | $2.14 | x |
| 2025-12-31 | $-0.34 | $2.14 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Jyong Biotech Ltd. Ordinary Shares utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (0.00%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $4.40K |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.87 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.67 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-992.70K |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $632.90K |
| 2025 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.18 Million |
Industry Comparison
This section compares Jyong Biotech Ltd. Ordinary Shares's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $219,658,634
- Average return on equity (ROE) among peers: -31.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Jyong Biotech Ltd. Ordinary Shares (MENS) | $-24.91 Million | 0.00% | N/A | $156.62 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $121.06 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $316.23 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $-41.16 Million | 0.00% | 0.00x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $136.85 Million | -50.75% | 0.43x | $960.81 Million |
| ABVC Biopharma Inc (ABVC) | $-2.01 Million | 0.00% | 0.00x | $28.25 Million |
| Abivax SA American Depositary Shares (ABVX) | $196.01 Million | -75.37% | 0.67x | $8.21 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $699.13 Million | -33.65% | 0.12x | $4.38 Billion |
About Jyong Biotech Ltd. Ordinary Shares
Jyong Biotech Ltd., a science-driven biotechnology company, engages in the development and commercialization of plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops Botreso, for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for t… Read more